CERo Therapeutics (NASDAQ:CERO) Reaches New 1-Year Low – Here’s Why

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $3.35 and last traded at $3.35, with a volume of 174874 shares traded. The stock had previously closed at $5.23.

CERo Therapeutics Price Performance

The stock’s 50 day moving average price is $12.00 and its 200 day moving average price is $13.71.

Insider Activity

In other news, major shareholder Bioventures Opportunities G. Yk sold 29,989 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.00, for a total value of $179,934.00. Following the completion of the sale, the insider now directly owns 130,051 shares of the company’s stock, valued at $780,306. This represents a 18.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 64,300 shares of company stock worth $529,409 over the last quarter. 18.00% of the stock is currently owned by corporate insiders.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.